A comparison of cancer stem cell markers and nonclassical major histocompatibility complex antigens in colorectal tumor and noncancerous tissues

Torre, 2015, Global cancer statistics, 2012, CA Cancer J Clin, 65, 87, 10.3322/caac.21262

Hong, 2015, Expression of the cancer stem cell markers CD44 and CD133 in colorectal cancer: an immunohistochemical staining analysis, Ann Coloproctol, 31, 84, 10.3393/ac.2015.31.3.84

Van Cutsem, 2009, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, 360, 1408, 10.1056/NEJMoa0805019

Reya, 2001, Stem cells, cancer, and cancer stem cells, Nature, 414, 105, 10.1038/35102167

Cherciu, 2014, Stem cells, colorectal cancer and cancer stem cell markers correlations, Curr Health Sci J, 40, 153

Sahlberg, 2014, Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells, PLoS One, 9, e94621, 10.1371/journal.pone.0094621

Ou, 2013, Fibronectin extra domain a (EDA) sustains CD133+/CD44+ subpopulation of colorectal cancer cells, Stem Cell Res, 11, 820, 10.1016/j.scr.2013.05.009

Iv Santaliz-Ruiz, 2014, Emerging role of Nanog in tumorigenesis and cancer stem cells, Int J Cancer, 135, 2741, 10.1002/ijc.28690

Peitzsch, 2013, Discovery of the cancer stem cell related determinants of radioresistance, Radiother Oncol, 108, 378, 10.1016/j.radonc.2013.06.003

De Angelis, 2016, Cancer stem cell–based models of colorectal cancer reveal molecular determinants of therapy resistance, Stem Cells Transl Med, 5, 511, 10.5966/sctm.2015-0214

Rao, 2013, Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs, Acta Pharmacol Sin, 34, 793, 10.1038/aps.2013.56

Callahan, 2013, At the bedside: CTLA-4– and PD-1–blocking antibodies in cancer immunotherapy, J Leukoc Biol, 94, 41, 10.1189/jlb.1212631

Lebrun, 2012, The dual role of TGF in human cancer: from tumor suppression to cancer metastasis, ISRN Mol Biol, e381428

Peng, 2016, Loss of PTEN promotes resistance to T cell–mediated immunotherapy, Cancer Discov, 6, 202, 10.1158/2159-8290.CD-15-0283

Holmgaard, 2013, Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4, J Exp Med, 210, 1389, 10.1084/jem.20130066

Amiot, 2011, Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?, Cell Mol Life Sci, 68, 417, 10.1007/s00018-010-0583-4

Bossard, 2012, HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression, Int J Cancer, 131, 855, 10.1002/ijc.26453

Lin, 2011, HLA-F expression is a prognostic factor in patients with non–small-cell lung cancer, Lung Cancer, 74, 504, 10.1016/j.lungcan.2011.04.006

Eskicioğlu, 2015, The association of HLA-G and immune markers in recurrent miscarriages, J Matern Fetal Neonatal Med, 1, 10.3109/14767058.2015.1114085

López-Botet, 1999, How do NK cells sense the expression of HLA-G class Ib molecules?, Semin Cancer Biol, 9, 19, 10.1006/scbi.1998.0107

Gao, 2000, Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8alphaalpha, J Biol Chem, 275, 15232, 10.1074/jbc.275.20.15232

Fons, 2006, Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells, Blood, 108, 2608, 10.1182/blood-2005-12-019919

Iwaszko, 2011, Clinical significance of the HLA-E and CD94/NKG2 interaction, Arch Immunol Ther Exp (Warsz), 59, 353, 10.1007/s00005-011-0137-y

Morandi, 2014, Interactions between HLA-G and HLA-E in physiological and pathological conditions, Immunol Toler, 5, 394

Teklemariam, 2012, Full-length HLA-G1 and truncated HLA-G3 differentially increase HLA-E surface localization, Hum Immunol, 73, 898, 10.1016/j.humimm.2012.06.007

Naji, 2007, Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways, Hum Immunol, 68, 233, 10.1016/j.humimm.2006.10.017

Zeestraten, 2014, Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients, Br J Cancer, 110, 459, 10.1038/bjc.2013.696

Reimers, 2014, Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study, BMC Cancer, 14, 486, 10.1186/1471-2407-14-486

Guo, 2015, Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients, Cell Immunol, 293, 10, 10.1016/j.cellimm.2014.10.003

Benevolo, 2011, High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis, J Transl Med, 9, 184, 10.1186/1479-5876-9-184

Mizrak, 2008, CD133: molecule of the moment, J Pathol, 214, 3, 10.1002/path.2283

Mia-Jan, 2013, Expression of CD133 in neuroendocrine neoplasms of the digestive tract: a detailed immunohistochemical analysis, Tohoku J Exp Med, 229, 301, 10.1620/tjem.229.301

Zeilstra, 2013, CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status, PLoS One, 8, e72849, 10.1371/journal.pone.0072849

Fromont Hankard, 1998, CD44 variant expression in inflammatory colonic mucosa is not disease specific but associated with increased crypt cell proliferation, Histopathology, 32, 317, 10.1046/j.1365-2559.1998.00404.x

Schulenburg, 2006, Neoplastic stem cells: a novel therapeutic target in clinical oncology, Cancer, 107, 2512, 10.1002/cncr.22277

Jing, 2015, Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases, Int J Oncol, 10.3892/ijo.2015.2844

Galizia, 2012, Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer, Arch Surg Chic Ill 1960, 147, 18

Wang, 2012, Prognostic role of CD133 expression in colorectal cancer: a meta-analysis, BMC Cancer, 12, 573, 10.1186/1471-2407-12-573

Amini, 2014, The expressions of stem cell markers: Oct4, nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in bladder, colon, and prostate cancer, and certain cancer cell lines, Anat Cell Biol, 47, 1, 10.5115/acb.2014.47.1.1

Liu, 2013, Pluripotency transcription factors and cancer stem cells: small genes make a big difference, Chin J Cancer, 32, 483

Hawkins, 2014, Cell signalling pathways underlying induced pluripotent stem cell reprogramming, World J Stem Cells, 6, 620, 10.4252/wjsc.v6.i5.620

Saigusa, 2009, Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy, Ann Surg Oncol, 16, 3488, 10.1245/s10434-009-0617-z

Xu, 2012, Nanog: a potential biomarker for liver metastasis of colorectal cancer, Dig Dis Sci, 57, 2340, 10.1007/s10620-012-2182-8